Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Latest News about Eisai Co Ltd
Recent news which mentions Eisai Co Ltd
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
October 30, 2024
Tags
Earnings
Eisai Co Ltd
Health care industry
From
CNBC.com News
5 things to know before the stock market opens Monday
September 09, 2024
Tags
Business
5 Things to Know
Business News
From
CNBC.com News
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
September 08, 2024
Tags
Biotech and Pharmaceuticals
Health care industry
Eisai Co Ltd
From
CNBC.com News
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
July 30, 2024
Tags
Health care industry
Eisai Co Ltd
Biotech and Pharmaceuticals
From
CNBC.com News
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
July 30, 2024
Tags
Companies
US: News
Biotechnology
From
CNBC.com News
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
July 26, 2024
Tags
Biotech and Pharmaceuticals
Eli Lilly and Co
Eisai Co Ltd
From
CNBC.com News
Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
June 11, 2024
Tags
Eisai Co Ltd
Eli Lilly and Co
Mad Money
From
CNBC.com News
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
April 24, 2024
Tags
Biotechnology
Biogen Inc
Companies
From
CNBC.com News
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
March 08, 2024
Tags
Business
Pharmaceuticals
Companies
From
CNBC.com News
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
February 20, 2024
Tags
Biogen Inc
Biotech and Pharmaceuticals
Health & Science
From
CNBC.com News
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
February 13, 2024
Tags
Companies
US: News
Biotechnology
From
CNBC.com News
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
January 31, 2024
Tags
Health care industry
Eisai Co Ltd
Biotech and Pharmaceuticals
From
CNBC.com News
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
December 20, 2023
Tags
Business
Pharmaceuticals
Health & Science
From
CNBC.com News
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
December 02, 2023
Tags
Eli Lilly and Co
Eisai Co Ltd
Health care industry
From
CNBC.com News
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
October 25, 2023
Tags
Eisai Co Ltd
Health care industry
Biotech and Pharmaceuticals
From
CNBC.com News
5 things to know before the stock market opens Tuesday
July 18, 2023
Tags
Economy
Investing
Tesla Inc
From
CNBC.com News
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
July 17, 2023
Tags
Science
Breaking news
Business
From
CNBC.com News
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
July 08, 2023
Tags
Policy
Health care industry
Eisai Co Ltd
From
CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
July 07, 2023
Tags
Biotech and Pharmaceuticals
Regulations
Eisai Co Ltd
From
CNBC.com News
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
July 07, 2023
Tags
Meta Platforms Inc
Economy
Biogen Inc
From
CNBC.com News
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
July 07, 2023
Tags
Biotech and Pharmaceuticals
Biogen Inc
Social issues
From
CNBC.com News
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
July 06, 2023
Tags
Politics
Biotech and Pharmaceuticals
Policy
From
CNBC.com News
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval
June 09, 2023
Tags
Business News
Breaking News: Business
Health & Science
From
CNBC.com News
Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action
June 07, 2023
Tags
Biotech and Pharmaceuticals
Politics
Eisai Co Ltd
From
CNBC.com News
Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
May 12, 2023
Tags
Alzheimer's disease
Business
US: News
From
CNBC.com News
Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments
May 01, 2023
Tags
Policy
Health care industry
Eisai Co Ltd
From
CNBC.com News
Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
April 30, 2023
Tags
Pandemics
Politics
Quest Diagnostics Inc
From
CNBC.com News
Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says
April 26, 2023
Tags
Epidemics
US: News
Social issues
From
CNBC.com News
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
April 25, 2023
Tags
Biotech and Pharmaceuticals
Health care industry
Eisai Co Ltd
From
CNBC.com News
Alzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai says
April 06, 2023
Tags
Biotech and Pharmaceuticals
Eli Lilly and Co
Eisai Co Ltd
From
CNBC.com News
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.